Women Who Experience Menopause Before 40 Face 40% Higher Lifetime Risk of Heart Attacks, New Study Finds

Women who undergo natural menopause before age 40 face approximately a 40% greater lifetime risk of coronary heart disease, including fatal and nonfatal heart attacks, compared with those who experience menopause later, according to a large new study published March 18, 2026, in JAMA Cardiology.

The research, led by Northwestern Medicine and involving pooled data from U.S. cohorts, is the first to specifically quantify lifetime coronary heart disease (CHD) risk tied to premature menopause. It found that premature menopause—defined as natural cessation of menstruation before age 40—was linked to a 40% higher risk overall, with the association holding even after adjusting for traditional cardiovascular risk factors such as smoking, obesity, hypertension and diabetes.

Black women showed a slightly elevated risk at 41%, compared with 39% for white women, and are three times more likely than white women to experience premature menopause, amplifying the public health implications.

"Premature menopause should be recognized as a key marker for long-term cardiovascular vulnerability," said lead author Priya Freaney, MD, assistant professor of medicine in the Division of Cardiology at Northwestern University Feinberg School of Medicine. "This isn't just about when periods stop; it's a signal that estrogen exposure ends much earlier, potentially accelerating atherosclerosis and other heart disease processes."

The study builds on decades of evidence linking earlier menopause to heightened cardiovascular risks but advances the field by focusing on lifetime CHD incidence rather than shorter-term events. Previous meta-analyses had shown relative risks around 1.5 for premature menopause and coronary events, but this cohort analysis provides a clearer picture of cumulative burden over a woman's lifespan.

Premature menopause, also called premature ovarian insufficiency (POI) when occurring naturally, affects about 1-2% of women and can stem from genetic factors, autoimmune conditions, environmental exposures or idiopathic causes. Surgical menopause from bilateral oophorectomy before 40 carries similar or sometimes higher risks due to abrupt hormone loss.

Estrogen plays a protective role in cardiovascular health by helping maintain favorable cholesterol profiles, supporting vascular flexibility and reducing inflammation. Its early decline in premature menopause is thought to contribute to faster plaque buildup in arteries, elevated blood pressure and metabolic changes that compound over time.

The JAMA Cardiology paper analyzed data from multiple U.S. cohorts tracking postmenopausal women, calculating lifetime risk using competing-risk models that account for death from other causes. Results showed consistent associations across racial groups, underscoring that premature menopause acts as an independent risk enhancer beyond conventional factors.

Experts emphasize that the finding does not imply causation in every case—premature menopause may sometimes reflect underlying conditions that also drive heart disease—but the link persists after statistical adjustments.

"Even if we don't fully understand the mechanisms yet, the signal is strong enough to warrant earlier and more aggressive cardiovascular screening for these women," Freaney said.

Guidelines from organizations like the American Heart Association and the North American Menopause Society already classify early menopause (before 45) as a risk-enhancing factor for atherosclerotic cardiovascular disease. The new data strengthens calls to incorporate age at menopause into routine risk assessments, such as the ASCVD risk estimator or Framingham scores.

Hormone therapy (HT) remains a debated intervention. For women with POI, major guidelines recommend systemic estrogen therapy—typically combined with progestin if the uterus is intact—until at least the average age of natural menopause (around 51-52) to mitigate symptoms and potentially reduce long-term risks, including cardiovascular ones. Observational data suggest HT initiated soon after menopause onset may offer cardioprotective benefits in younger women, though randomized trials in older populations showed mixed results.

The study did not directly evaluate HT use, but authors noted that many women with premature menopause do not receive adequate hormone replacement due to concerns over breast cancer or other risks, potentially exacerbating their vulnerability.

Lifestyle modifications offer another layer of protection. A 2025 analysis in Heart journal found that high adherence to healthy behaviors—such as not smoking, maintaining physical activity, healthy diet, moderate alcohol intake and normal body weight—reduced CVD odds by 23% overall and by 52% in women with premature menopause.

"Women with premature menopause have a window to act," said one co-author. "Aggressive management of modifiable risks can substantially offset the added burden from early estrogen loss."

Broader context highlights disparities. Black women not only face higher rates of premature menopause but also bear a disproportionate CVD burden due to systemic factors like access to care, chronic stress and higher prevalence of hypertension and diabetes.

The research arrives amid growing attention to women's cardiovascular health. Heart disease remains the leading cause of death for women in the U.S., and recent projections warn that nearly 60% of women could have some form of CVD by 2050, up from current levels, partly due to aging populations and rising risk factors starting earlier in life.

For clinicians, the takeaway is straightforward: Ask about age at menopause during patient histories, especially for women in their 40s and 50s presenting with risk factors or symptoms. Early identification allows tailored prevention—statin therapy if indicated, blood pressure control, smoking cessation and lifestyle counseling.

Patient advocacy groups stress education. Many women with premature menopause report feeling dismissed when raising concerns about long-term health, including heart risks.

As research evolves, future studies may clarify mechanisms—such as genetic links, inflammatory pathways or vascular biomarkers—and test targeted interventions. For now, the March 2026 JAMA Cardiology findings reinforce premature menopause as a critical, underrecognized signal for lifelong heart protection strategies.

Women experiencing irregular periods or sudden cessation before 40 should consult a healthcare provider promptly for evaluation, which may include hormone testing and counseling on risks and options.

With proactive care, the elevated heart attack risk tied to premature menopause need not translate to inevitable outcomes.